Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT3 | P42568 | 1/20 | 0.37 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1886019 | 0.89 | KDM4E (0.41) | MLLT3MLLT1KDM4E | |
| SCHEMBL2493245 | 0.86 | MLLT3 (0.36) | MLLT3MLLT1SCN9ASCN10ANOTUM | |
| SCHEMBL2497581 | 0.84 | HSD17B14 (0.39) | MLLT3MLLT1SCN9ASCN10AGRM5 | |
| SCHEMBL2497610 | 0.84 | SCN9A (0.35) | MLLT3MLLT1SCN9ASCN10AGRM5 | |
| SCHEMBL2493511 | 0.84 | CYP11B2 (0.38) | MLLT3MLLT1SCN9ANOTUM | |
| SCHEMBL2498898 | 0.84 | KDM4C (0.36) | MLLT3MLLT1SCN9ASCN10AGRM5 | |
| SCHEMBL2497645 | 0.83 | DHFR (0.39) | MLLT3MLLT1NOTUMMAP3K5GRM5 | |
| SCHEMBL1877848 | 0.83 | NOTUM (0.54) | SCN9ANOTUMGRM5 | |
| SCHEMBL2493286 | 0.83 | MGLL (0.34) | MLLT3MLLT1SCN9ASCN10A | |
| SCHEMBL2494711 | 0.83 | TRPM8 (0.38) | MLLT3MLLT1SCN9ASCN10ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030339-B2 | Imidazole derivatives for the treatment of anxiety and related diseases | NEUROSEARCH A/S (DK) | 2011-10-04 | — | — | US | disclosed |
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | US | disclosed |
| EP-1937649-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES | NEUROSEARCH A/S (DK) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042546-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES | NEUROSEARCH A/S (DK) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | GABBR1, GABRB2, GABRB3 | MLLT3 3352/4885MLLT1 2892/4885SCN9A 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.